HemaTarget Profile Test is a comprehensive genomic profiling gene panel for blood cancers (hematologic malignancies) designed to assist physicians with disease stratification, prognosis and targeted therapy decisions. The test simultaneously sequences 131 cancer related genes (number of genes is subject to change) and examines the genomic changes associated with the development of blood cancers. The panel includes but is not limited to, acute and chronic leukemia (AML, ALL and CML), lymphomas, myelodysplastic syndrome (MDS) and multiple myeloma.
This panel profiles the DNA and RNA in the selected genes and certain non-coding regions related to drug metabolism, efficiency and toxicity and chemotherapy. Using NGS technology, the HemaTarget tests all classes of genomic alterations: base changes, insertions, deletions, copy number variations, and fusions (translocations) which are key drivers of oncogenic pathways in hematological cancers. The identified alterations can then be targeted by matched drug therapies.
HemaTarget is offered to every patient with a Hematologic malignancy. The test is a single comprehensive assay that provides valuable information relevant for:
First line treatment decisions (chemotherapy) .
Uniquely, AID Genomics HemaTarget Profile test includes identification of variants associated with:
Drug response .
Drug metabolism: guide treatment dosage.
Chemotherapy response: toxicity, dosage.
Dose associated event free survival (EFS).
Risk for graft versus host disease post allogenic stem cell transplantation.
One test needed- by interrogating DNA and RNA, this single test identifies all classes of genomic alterations: base changes, insertions and deletions, copy number variations, and fusions (translocations) which are key drivers of oncogenic pathways in hematological cancers.
First line treatment options- this advanced genomic profiling test provides information to guide personalized first line treatment decisions.
Small amounts of samples (bone marrow or peripheral blood) required- we can perform the test on a minute amount of DNA, much less then required by other service providers.
Stringent sequencing method used- we utilize a stringent sequencing and analysis method on all of HemaTarget’s tested genes which yields higher sensitivity and specificity rates.
DNA and RNA are extracted from the samples and enriched for the selected cancer-related genes/regions of the panel using a proprietary targeted capture system developed by AID Genomics. The captured products are sequenced on advanced Next-Generation Sequencing platforms, deep sequencing (or many reads of the same region) enables characterization of rare tumor variants.
Data analysis is performed using proprietary bioinformatics tools, and our medical experts then produce the results for the Test Report.
HemaTarget Profile Test report provides a table of variants with possible therapies, and relevant technical information regarding sequence depth of coverage, variant frequency and annotation of variants according to clinical databases. In the core of the report, complete information about the genomic alterations is provided with its etiology along with data regarding the possible treatments and detailed references to sustain the results which appear in the report.
Positive result – includes the following scenarios of reportable variables:
Variants with FDA approved drugs for the patient’s cancer type, or variants included in professional guidelines, are identified.
Variants predicting response to treatment for the patient’s cancer type based on well-powered studies are identified.
Variants predicting response to treatment approved by the FDA for a different type of cancer or variants that serve as inclusion criteria for clinical trials are identified.
Variants with plausible therapeutic significance based on pre-clinical trials are identified.
Variants with no known therapies are identified.
Negative result – a negative result indicates that no reportable variants were detected.